Health · 19 June 2026

CMA wins appeal in Pfizer drug case

NHS medicine costs jumped sharply after price rises for an epilepsy treatment, leading to years of legal action over alleged overcharging. A court has ruled the Competition Appeal Tribunal was wrong to overturn the Competition and Markets Authority’s findings against the drug company and its distributor. Spending on phenytoin sodium rose from about £2.3m a year before 2012 to more than £50m in 2013.

By BriefTea Editorial · 19 June 2026 at 14:29

Reported by City AM · How we write briefs

Get the app

More briefs

HealthGreat Ormond Street's Same-Day Test Finds Hidden Infections in Sick Children HealthImmune cell found to kill small cell lung cancer in lab tests HealthDiabetics sleeping 8+ hours face nearly double kidney disease risk HealthNo perfect age to start HRT, but benefits peak before 60, experts say HealthOver 12,000 fake weight-loss pens worth £2m seized in Birmingham raid HealthTrans patients in England to go on wards matching birth sex More health stories → Browse all stories →